KOSDAQBiotech & Pharma225220

Genolution

₩1,704▼ 2.57%2026-11-18 close
Market Cap
₩32.7B
Turnover
₩36,552,864
Volume
20K
Shares out.
19.2M
PER
—
PBR
0.5×
EPS
-₩464
Dividend Yield
0.00%

PER, EPS, PBR and BPS are calculated in-house from the last 4 quarters (2025Q4–2026Q3) · Dividend yield is based on ₩0 per share · Prices as of the 2026-11-18 close

01

Report overview

Mixed quarterly results as diversification advances

Genolution posted losses for three straight years through 2025, and its 2026 quarters have swung between a first-quarter profit and a renewed third-quarter net loss.

  1. 1

    Sales rose 31.8% to KRW 9.4 billion in 2025, but the operating loss stayed at KRW 8.64 billion.

  2. 2

    Operating losses have run for five straight quarters from Q3 2025 through Q3 2026, with the latest at KRW 1.97 billion.

  3. 3

    Net income attributable to controlling shareholders turned positive at KRW 597 million in Q1 2026, then swung to a KRW 4.64 billion loss in Q3.

  4. 4

    The company is widening its base from molecular diagnostics into RNAi-based bee and crop treatments, liquid-biopsy automation and a beauty-device subsidiary.

  5. 5

    A January 2026 share transfer agreement was set to raise co-CEO Kim Ki-ok's stake to 11.62%.

02

Business structure

Genolution develops and manufactures in-vitro diagnostic devices and reagents built on nucleic acid extraction technology. Its revenue base is molecular diagnostics, which supplies nucleic acid extraction reagents and automated instruments to laboratories and diagnostic institutions.

Jobkorea's company profile shows Bio-Rad product sales at 54 to 56 percent, nucleic acid extraction reagents at 30 to 34 percent and RNAi at 7 to 9 percent as of year-end 2025, but the splits differ by source, so they are read only as a rough picture.

An early-2025 Edaily report said molecular diagnostic devices accounted for about 51 percent of cumulative third-quarter sales. The RNAi business is sold in more than ten countries, according to the company profile.

In 2024 the company received the world's first product approval for a gene therapy against Chronic bee paralysis-type viral disease in honeybees. In July 2026 it added an RNAi crop-protection composition targeting a chili virus (BBWV2) to its pipeline.

In precision medicine it promotes an automated workflow linking separation and extraction of liquid-biopsy samples such as urine through to companion diagnostics. On the consumer side, a beauty-device subsidiary sells plasma skin-care devices in a B2C model and is pursuing medical device entry.

Customers are mainly B2B buyers such as research labs, government agencies and diagnostic institutions, and distributor agreements are expanding its sales network in the Daejeon and Chungcheong region.

03

Earnings trend

Quarterly revenue · Operating profit
RevenueOperating profit
Annual revenue · Operating profit
RevenueOperating profit
Quarterly results · Last 5 quarters
QuarterRevenueOperating profitOp. margin
2025Q3₩2.1B-₩2.4B−117.9%
2025Q4₩2.4B-₩2B−84.8%
2026Q1₩2.5B-₩1.4B−55.6%
2026Q2₩3.1B-₩1.6B−51.6%
2026Q3₩2.6B-₩2B−77.3%
Annual results
YearRevenueOperating profitNet income (parent)Op. marginROEDebt-to-equity
2022₩38.1B₩14.7B₩14.6B38.7%15.4%20.9%
2023₩9.8B-₩7.1B-₩5.5B−72.6%−6.3%29.4%
2024₩7.1B-₩9.2B-₩6.8B−128.4%−8.5%32.4%
2025₩9.4B-₩8.6B-₩11.6B−91.9%−17.0%38.2%

Consolidated basis (financial statements including subsidiaries) · Final figures from DART filings · Net income attributable to owners of the parent · Data as of 2026-11-18

04

Earnings analysis

Annual sales fell from KRW 38.1 billion in 2022 to KRW 9.76 billion in 2023, a 74.4% decline, and then to KRW 7.14 billion in 2024, down 26.9% and the smallest year in the 2022 to 2025 window. Sales recovered to KRW 9.4 billion in 2025, up 31.8%, but that is only a little above a quarter of the 2022 level.

The decline followed a peak of KRW 85.3 billion in 2020, a pattern that overlaps with falling demand for COVID-19 diagnostic reagents and instruments.

Operating income of KRW 14.7 billion in 2022 turned into an operating loss of KRW 7.09 billion in 2023, followed by an operating loss of KRW 9.16 billion in 2024 and KRW 8.64 billion in 2025, which makes three straight loss years. The operating margin improved from -128.4% in 2024 to -91.9% in 2025.

The net loss attributable to controlling shareholders reached KRW 11.6 billion in 2025, larger than the operating loss, which suggests non-operating items pulled earnings lower; the detailed items should be checked in the full annual report.

The debt-to-equity ratio rose from 20.9% in 2022 to 38.2% in 2025, with year-end total liabilities of KRW 25.9 billion and total equity of KRW 67.9 billion. Equity attributable to controlling shareholders of KRW 68.4 billion exceeds total equity, which means non-controlling interests are negative.

Operating cash flow went from KRW 13.6 billion in 2022 to -KRW 1.14 billion in 2023, -KRW 1.43 billion in 2024 and -KRW 7.01 billion in 2025, a widening outflow.

Quarterly sales rose from KRW 2.07 billion in Q3 2025 to KRW 3.09 billion in Q2 2026, then fell 17.5% quarter on quarter to KRW 2.55 billion in Q3 2026, still up 23.3% year on year. Operating loss narrowed from KRW 2.44 billion in Q3 2025 to KRW 1.97 billion in Q3 2026.

Net income attributable to controlling shareholders, however, was KRW 597 million in Q1 2026 and KRW 775 million in Q2, before a KRW 4.64 billion loss in Q3.

According to the company, the first-quarter profit reflected non-operating items such as foreign exchange gains and equity valuation gains at an investee, while package supply through a distribution partnership drove sales growth.

The combined net loss attributable to controlling shareholders over the latest four quarters is KRW 8.38 billion.

05

Industry analysis

Molecular diagnostics demand has moved with the pandemic cycle. Edaily reported that the company's sales peaked at KRW 85.3 billion in 2020 and fell to KRW 38.1 billion in 2022, a decline tied to COVID-19 test kit demand for nucleic acid extraction reagents and instruments.

After COVID-19 shifted toward an endemic pattern, sales of extraction reagents and instruments slowed. In 2026 the company said recombinant variants were spreading across 33 countries and signs of a resurgence were appearing, and it has positioned variant analysis and wastewater-based surveillance as business pillars.

According to Grand View Research, as cited in a 2026 report, the global liquid biopsy market is expected to grow from USD 13.6 billion in 2025 to USD 32.57 billion by 2033.

In precision medicine, the speed at which research results become commercial products matters, and industry commentary suggests firms with automated core technology may have an advantage.

RNAi crop protection is expanding into a pipeline for chili virus control, alongside its honeybee treatment, forming an RNA-based product group for agriculture and livestock. Competition in reagents and instruments depends heavily on demand from research institutes and government agencies and on distribution networks.

The company said that package supply of its extraction reagents and instruments combined with a partner's specialty reagent line drew a positive response from laboratories and government agencies.

06

Outlook

In an April 2026 report, the company set a target of officially launching its automated instrument Geno-N in the third quarter of 2026. The instrument automates pre-processing for next-generation sequencing.

At the ASN Kidney Week 2026 meeting in October 2026, the company said it would pursue the liquid biopsy and exosome separation market with an automated solution linking separation and extraction of urine and other liquid samples through to companion diagnostics.

It ran a standalone booth and held B2B partnership meetings with multinational healthcare companies there. The company calls its precision medicine division the core driver and plans to pursue business opportunities in North America and other global markets.

On November 18, 2026, a subsidiary announced a patent registration for an ozone-reduction technology in its plasma skin-care device, and it is pursuing B2C and B2B sales of products using that technology as well as entry into medical devices.

The company says its RNAi-based honeybee treatment improved bee mortality by more than 60 percent in clinical trials.

On governance, a January 20, 2026 share transfer agreement transferred the largest shareholder's stake to co-CEO Kim Ki-ok, with payment and delivery scheduled for February 19, 2026, which would raise his stake to 11.62 percent.

The next periodic report is the 2026 annual report, with a statutory filing deadline in late March 2027, and it will fix full-year sales, operating margin and operating cash flow. The first-quarter 2027 report then shows whether operating income has moved into profit.

07

Valuation

PER
—
PBR
0.5×
ROE
-12.1%
EPS
-₩464
BPS
₩3,615
Dividend per share
₩0

Because the latest four quarters show a net loss, no earnings-based multiple is calculated. The price-to-book ratio is below 1x, which means the shares trade under the book value of net assets.

Market capitalization is small relative to total equity of KRW 67.9 billion, so the gap between asset value and continued losses is the central point of market valuation. The dividend yield is effectively nil, so the case for shareholder returns is thin.

Multiples built on the 2020 COVID-19 peak of KRW 85.3 billion in sales are hard to use as a comparison base for current results. For an earnings multiple to be calculated again, operating-level profit has to continue, and the recent quarterly profit was affected by non-operating items.

A factual comparison with listed peers that are also loss-making gives a clearer read on where the company sits.

PER, EPS, PBR and BPS are all calculated in-house (the same method as Naver and Toss) · Dividend yield = cash dividend per share from DART filings (supplemented by KRX) ÷ current price · As of 2026-11-18

08

Bull factors

Narrowing quarterly operating loss

The operating loss in Q3 2026 was KRW 1.97 billion, down from KRW 2.44 billion in Q3 2025. Net income attributable to controlling shareholders turned positive at KRW 597 million in Q1 2026 and stayed positive at KRW 775 million in Q2. Quarterly sales climbed from KRW 2.07 billion in Q3 2025 to KRW 3.09 billion in Q2 2026.

Diversifying RNA-based product lines

After securing approval for its honeybee treatment, the company announced an RNAi crop-protection composition targeting a chili virus in July 2026. The company said its honeybee treatment improved mortality by more than 60 percent in clinical trials. Its RNA synthesis capability is being used to extend the product range into agriculture and livestock.

Precision medicine and wider distribution

The company said package supply after its distributor agreement, which combined extraction reagents and instruments with specialty reagents, drew a positive response from laboratories and government agencies.

It is entering the research infrastructure market for precision medicine through liquid biopsy and exosome automation. Grand View Research projects that market to grow from USD 13.6 billion in 2025 to USD 32.57 billion by 2033.

09

Bear factors

Five straight quarters of operating losses

Operating losses have continued for five straight quarters from Q3 2025 through Q3 2026. The 2025 operating loss of KRW 8.64 billion extends a three-year run of losses that began in 2023. The 2025 operating margin of -91.9% shows losses are still large relative to sales.

Questions over the quality of profit

According to the company, the first-quarter 2026 profit reflected non-operating items such as foreign exchange gains and equity valuation gains. An operating loss of KRW 1.38 billion remained in that quarter, so operating-level profitability is still some distance away.

In Q3 2026 the net loss attributable to controlling shareholders of KRW 4.64 billion reversed the earlier profit.

Weaker cash flow and rising leverage

Operating cash flow moved from KRW 13.6 billion in 2022 to an outflow of -KRW 7.01 billion in 2025. The debt-to-equity ratio rose from 20.9% in 2022 to 38.2% in 2025. Total equity remains at KRW 67.9 billion, but continued losses would erode that capital base.

10

Risk factors

Sales scale and volatility

Sales fell from KRW 85.3 billion in 2020 to KRW 38.1 billion in 2022 and KRW 7.14 billion in 2024. The 2025 recovery to KRW 9.4 billion came from a base where quarterly sales still move around the KRW 2 billion range. At that scale, a change in one or two contracts can shift the sales trend noticeably.

FX and non-operating swings

The company said it secured foreign exchange gains through active currency management. If those gains shrink as exchange rates move, net income could tilt back toward losses.

The 2025 net loss attributable to controlling shareholders of KRW 11.6 billion, larger than the operating loss, also points to sizable non-operating swings.

Governance and shareholding changes

On December 29, 2025, co-CEO Kim Ki-ok bought 190,000 shares off-market, raising his stake to 7.39 percent. A January 20, 2026 agreement to transfer the largest shareholder's stake was set to raise his holding to 11.62 percent.

Changes in the largest shareholder and the co-CEO's stake are variables that need to be tracked through disclosures.

11

What to watch next

  1. Late March 2027

    This is the filing deadline for the 2026 annual report. It is the point to check how full-year sales, operating margin and operating cash flow compare with the 2025 figures, and the fourth-quarter 2026 results are finalized in the same filing.

  2. Mid-May 2027

    This is the filing point for the first-quarter 2027 report. It shows whether the operating loss keeps narrowing and net income attributable to controlling shareholders stays positive, as in early 2026, and whether operating-level profit appears.

  3. First half of 2027 (disclosure date not set)

    The disclosure of the official launch of the Geno-N instrument, which was targeted for Q3 2026, and whether it shows up in sales is a key checkpoint. The contribution of the liquid biopsy automation business to quarterly sales should be tracked at the same time.

12

Overall view

Genolution's sales fell from KRW 38.1 billion in 2022 to KRW 7.14 billion in 2024 before recovering to KRW 9.4 billion in 2025, and operating results have been loss-making for three straight years from 2023 through 2025.

In 2026, quarterly earnings have been mixed, with a first-quarter profit attributable to controlling shareholders, a second-quarter profit, and a KRW 4.64 billion net loss in the third quarter.

The operating loss narrowed from KRW 2.44 billion in Q3 2025 to KRW 1.97 billion in Q3 2026, but operating losses have now run for five straight quarters. According to the company, the first-quarter profit reflected non-operating items such as foreign exchange and equity valuation gains.

The business is broadening into RNAi honeybee treatments, crop protection, liquid biopsy automation and a beauty-device subsidiary, although Jobkorea's profile puts the RNAi segment at roughly 7 to 9 percent of sales.

The debt-to-equity ratio rose from 20.9% in 2022 to 38.2% in 2025, and the operating cash outflow widened. The next checkpoints are whether operating-level profit appears and how cash flow looks in the 2026 annual report and the first-quarter 2027 report.

13

Sources

  1. Korea Exchange (KRX) — Prices · Market Cap · Volume
  2. FSS electronic disclosure system (DART) — Financial statements · Dividend filings
Show 18 more articles and sources
  1. comp.wisereport.co.kr
  2. jobkorea.co.kr
  3. comp.fnguide.com
  4. pharm.edaily.co.kr
  5. ggilbo.com
  6. pharm.edaily.co.kr
  7. newspim.com
  8. dailyinvest.kr
  9. m.news.nate.com
  10. newspim.com
  11. view.asiae.co.kr
  12. hankyung.com
  13. newstown.co.kr
  14. news.nate.com
  15. newspim.com
  16. specialtimes.co.kr
  17. newspim.com
  18. medifonews.com

Report written 2026-11-18 · Data as of 2026-11-17

This content is AI analysis of market data and web search results, provided for information only. It is not a solicitation or recommendation to invest. Investment decisions and their consequences are the investor's own responsibility. Data may be delayed or contain errors.

Other reports in this industry

View industry analysis